How different terminology for ductal carcinoma in situ (DCIS) impacts women's concern and management preferences: A qualitative study

Breast

Volumn 24, Issue 5, 2015, Pages 673-679

  Nickel, Brooke ^a,b   Barratt, Alexandra ^a,b   Hersch, Jolyn ^a,b   Moynihan, Ray ^c   Irwig, Les ^a   McCaffery, Kirsten ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c BOND UNIVERSITY   (Australia)

Author keywords

Communication; Ductal carcinoma in situ; Overtreatment; Terminology; Treatment preferences; Watchful waiting

Indexed keywords

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIAN; CANCER SCREENING; CLINICAL ARTICLE; EDUCATIONAL STATUS; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MEDICAL TERMINOLOGY; MIDDLE AGED; PATIENT PREFERENCE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; TREATMENT PLANNING; WOMEN'S HEALTH; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DECISION MAKING; FEAR; INTERVIEW; NOMENCLATURE; PROCEDURES; PSYCHOLOGY; UNNECESSARY PROCEDURE; WATCHFUL WAITING;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHOICE BEHAVIOR; FEAR; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERVIEWS AS TOPIC; MIDDLE AGED; PATIENT PREFERENCE; QUALITATIVE RESEARCH; TERMINOLOGY AS TOPIC; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 84952638922     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.08.004     Document Type: Article

References (43)

1. Wallis M.G., Clements K., Kearins O., Ball G., Macartney J., Lawrence G.M. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 2012, 106(10):1611-1617.
2. American Cancer Society Cancer facts & figures Atlanta 2015 Available from:, [cited 22.01.15]. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
3. Welch H.G., Schwartz L.M., Woloshin S. Over-diagnosed: making people sick in pursuit of health 2011, Beacon Press, Boston, MA.
4. Erbas B., Provenzano E., Armes J., Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 2006, 97(2):135-144.
5. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010, 2010(41):139-141.
6. Marmot M.G., Altman D.G., Cameron D.A., Dewar J.A., Thompson S.G., Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013, 108(11):2205-2240.
7. Tuttle T.M., Jarosek S., Habermann E.B., Arrington A., Abraham A., Morris T.J., et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009, 27(9):1362-1367.
8. Gomez S.L., Lichtensztajn D., Kurian A.W., Telli M.L., Chang E.T., Keegan T.H., et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. J Clin Oncol 2010, 28(10):e155-e157.
9. Kummerow K.L., Du L., Penson D.F., Shyr Y., Hooks M.A. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015, 150(1):9-16.
10. Cancer Research UK A trial comparing surgery with active monitoring for low risk DCIS (LORIS) Available from:, [cited 09.02.15]. http://www.cancerresearchuk.org/about-cancer/trials/a-trial-comparing-surgery-with-active-monitoring-for-low-risk-dcis-loris.
11. Elshof L.E., Tryfonidis K., Slaets L., van Leeuwen-Stok A.E., Skinner V.P., Dif N., et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - the LORD study. Eur J Cancer 2015, 51(12):1497-1510.
12. National Cancer Institute NCI dictionary of cancer terms: watchful waiting 2014 Available from:. http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45942.
13. Esserman L., Shieh Y., Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009, 302(15):1685-1692.
14. Esserman L.J., Thompson I.M., Reid B., Nelson P., Ransohoff D.F., Welch H.G., et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 2014, 15(6):e234-e242.
15. Davey C., White V., Warne C., Kitchen P., Villanueva E., Erbas B. Understanding a ductal carcinoma in situ diagnosis: patient views and surgeon descriptions. Eur J Cancer Care (Engl) 2011, 20(6):776-784.
16. De Morgan S., Redman S., White K.J., Cakir B., Boyages J. "Well, have I got cancer or haven't I?" The psycho-social issues for women diagnosed with ductal carcinoma in situ. Health Expect 2002, 5(4):310-318.
17. De Morgan S., Redman S., D'Este C., Rogers K. Knowledge, satisfaction with information, decisional conflict and psychological morbidity amongst women diagnosed with ductal carcinoma in situ (DCIS). Patient Educ Couns 2011, 84(1):62-68.
18. Partridge A., Adloff K., Blood E., Dees E.C., Kaelin C., Golshan M., et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 2008, 100(4):243-251.
19. van Gestel Y.R., Voogd A.C., Vingerhoets A.J., Mols F., Nieuwenhuijzen G.A., van Driel O.J., et al. A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 2007, 43(3):549-556.
20. Rakovitch E., Franssen E., Kim J., Ackerman I., Pignol J.P., Paszat L., et al. A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003, 77(3):285-293.
21. Fallowfield L., Matthews L., Francis A., Jenkins V., Rea D. Low grade ductal carcinoma in situ (DCIS): how best to describe it?. Breast 2014, 23(5):693-696.
22. Allegra C.J., Aberle D.R., Ganschow P., Hahn S.M., Lee C.N., Millon-Underwood S., et al. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements 2009, 26(2):1-27.
23. Esserman L.J., Thompson I.M., Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013, 310(8):797-798.
24. Gierisch J.M., Myers E.R., Schmit K.M., Crowley M.J., McCrory D.C., Chatterjee R., et al. Prioritization of research addressing management strategies for ductal carcinoma in situ. Ann Intern Med 2014, 160(7):484-491.
25. Omer Z.B., Hwang E.S., Esserman L.J., Howe R., Ozanne E.M. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med 2013, 173(19):1830-1831.
26. Moynihan R., Nickel B., Hersch J., Beller E., Doust J., Compton S., et al. Public opinions about overdiagnosis: a national community survey. PLoS One 2015, 10(5):e0125165.
27. Ritchie J.S.L., O'Connor W. Carrying out qualitative analysis. Qualitative research practice: a guide for social science students and researchers 2003, Sage, London. J.S.L. Ritchie (Ed.).
28. Pope C., Ziebland S., Mays N. Qualitative research in health care. Analysing qualitative data. BMJ 2000, 320(7227):114-116.
29. Hewitt-Taylor J. Use of constant comparative analysis in qualitative research. Nurs Stand 2001, 15(42):39-42.
30. Tavassoli F.A. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol 1998, 11(2):140-154.
31. Sagara Y., Mallory M.A., Wong S., Aydogan F., DeSantis S., Barry W.T., et al. Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg 2015, 150(8):739-745.
32. Fagerlin A., Zikmund-Fisher B.J., Ubel P.A. Cure me even if it kills me: preferences for invasive cancer treatment. Med Decis Mak 2005, 25(6):614-619.
33. Xu J., Neale A.V., Dailey R.K., Eggly S., Schwartz K.L. Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med 2012, 25(6):763-770.
34. Holmboe E.S., Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med 2000, 15(10):694-701.
35. Fallowfield L., Francis A., Catt S., Mackenzie M., Jenkins V. Time for a low-risk DCIS trial: harnessing public and patient involvement. Lancet Oncol 2012, 13(12):1183-1185.
36. Davison B.J., Oliffe J.L., Pickles T., Mroz L. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum 2009, 36(1):89-96.
37. Davison B.J., Breckon E. Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. Patient Educ Couns 2012, 87(3):369-374.
38. Prinjha S., Evans J., McPherson A. Women's information needs about ductal carcinoma in situ before mammographic screening and after diagnosis: a qualitative study. J Med Screen 2006, 13(3):110-114.
39. Virnig B.A., Tuttle T.M., Shamliyan T., Kane R.L. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010, 102(3):170-178.
40. Forbes L.J., Simon A.E., Warburton F., Boniface D., Brain K.E., Dessaix A., et al. Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival?. Br J Cancer 2013, 108(2):292-300.
41. Calhoun B.C., Livasy C.A. Mitigating overdiagnosis and overtreatment in breast cancer: what is the role of the pathologist?. Arch Pathol Lab Med 2014, 138(11):1428-1431.
42. Partridge A.H., Elmore J.G., Saslow D., McCaskill-Stevens W., Schnitt S.J. Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop. CA Cancer J Clin 2012, 62(3):203-210.
43. Francis A., Fallowfield L., Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol R Coll Radiol 2015, 27(1):6-8.